GlycoMimetics Total Assets 2012-2025 | CBIO
GlycoMimetics total assets from 2012 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
GlycoMimetics Annual Total Assets
(Millions of US $) |
| 2024 |
$11 |
| 2023 |
$45 |
| 2022 |
$52 |
| 2021 |
$94 |
| 2020 |
$143 |
| 2019 |
$168 |
| 2018 |
$215 |
| 2017 |
$129 |
| 2016 |
$42 |
| 2015 |
$48 |
| 2014 |
$57 |
| 2013 |
$5 |
| 2012 |
$18 |
| 2011 |
$29 |
GlycoMimetics Quarterly Total Assets
(Millions of US $) |
| 2025-03-31 |
$6 |
| 2024-12-31 |
$11 |
| 2024-09-30 |
$16 |
| 2024-06-30 |
$24 |
| 2024-03-31 |
$34 |
| 2023-12-31 |
$45 |
| 2023-09-30 |
$53 |
| 2023-06-30 |
$62 |
| 2023-03-31 |
$69 |
| 2022-12-31 |
$52 |
| 2022-09-30 |
$56 |
| 2022-06-30 |
$65 |
| 2022-03-31 |
$81 |
| 2021-12-31 |
$94 |
| 2021-09-30 |
$108 |
| 2021-06-30 |
$124 |
| 2021-03-31 |
$138 |
| 2020-12-31 |
$143 |
| 2020-09-30 |
$150 |
| 2020-06-30 |
$158 |
| 2020-03-31 |
$162 |
| 2019-12-31 |
$168 |
| 2019-09-30 |
$180 |
| 2019-06-30 |
$192 |
| 2019-03-31 |
$204 |
| 2018-12-31 |
$215 |
| 2018-09-30 |
$225 |
| 2018-06-30 |
$236 |
| 2018-03-31 |
$247 |
| 2017-12-31 |
$129 |
| 2017-09-30 |
$116 |
| 2017-06-30 |
$122 |
| 2017-03-31 |
$37 |
| 2016-12-31 |
$42 |
| 2016-09-30 |
$48 |
| 2016-06-30 |
$56 |
| 2016-03-31 |
$41 |
| 2015-12-31 |
$48 |
| 2015-09-30 |
$56 |
| 2015-06-30 |
$62 |
| 2015-03-31 |
$48 |
| 2014-12-31 |
$57 |
| 2014-09-30 |
$62 |
| 2014-06-30 |
$68 |
| 2014-03-31 |
$58 |
| 2013-12-31 |
$5 |
| 2013-09-30 |
$10 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
$0 |
| 2012-09-30 |
$0 |
| 2011-12-31 |
$29 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
| OncoCyte (IMDX) |
United States |
$0.090B |
0.00 |
